MedTrace Logo

Inter Cohorts and Clinical Centres Collaborations of Subjects Co-infected With HIV and HCV

NCT03324633 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1850

Last updated 2023-08-02

No results posted yet for this study

Summary

The ANRS CO13 HEPAVIH cohort is a prospective and multicentric cohort created in 2005 with the originality to cover two therapeutic domains of key importance, AIDS and hepatitis C. The cohort, is unique in Europe with more than 1800 participants followed over 10 years including quality of life and compliance to treatment data.

Conditions

  • HIV
  • Hepatitis C

Sponsors & Collaborators

  • Bristol-Myers Squibb

    collaborator INDUSTRY

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Merck Serono International SA

    collaborator INDUSTRY

  • Roche Pharma AG

    collaborator INDUSTRY

  • Schering-Plough

    collaborator INDUSTRY

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Dominique Salmon, MDPhD · Assistance Publique des Hôpitaux de Paris -Université Paris Descartes

  • Linda Wittkop, MDPhD · Inserm U1219 CHU de Bordeaux-Université de Bordeaux

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2017-09-30
Completion
2022-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03324633 on ClinicalTrials.gov